New study aims to predict cancer return in Low-Risk patients
NCT ID NCT04604613
First seen Mar 10, 2026 · Last updated Apr 30, 2026 · Updated 6 times
Summary
This study looks at whether molecular testing and lymph node mapping can help predict the risk of endometrial cancer returning in patients with low-risk cancer. About 518 people with early-stage, low-grade endometrial cancer will be followed for two years after surgery. The goal is to improve how doctors identify who might need extra monitoring or treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIGO GRADE 1 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.